New drug cocktail could spare kidney transplant patients from lifelong steroids
NCT ID NCT02711202
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a new combination of two drugs, Alemtuzumab and Infliximab, given right after a kidney transplant to prevent rejection. The goal was to see if patients could avoid long-term steroids and calcineurin inhibitors. Twenty first-time kidney transplant recipients were enrolled and followed for one year to check survival, graft function, and rejection rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alemtuzumab and Infliximab
What this could lead to
If successful, this approach could reduce the need for long-term steroids and calcineurin inhibitors after kidney transplant, potentially lowering side effects.
What could go wrong
This is a very small pilot study with only 20 patients, so results may not apply to everyone. The new regimen may not prevent rejection as well as standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.